Frontage Holdings (方达控股) Post-IPO Trading Update: Strong Demand and Volume but Fairly Valued
Frontage Holdings IPO attracted strong demand and was priced at the high end of the IPO pricing. In our previous insight, we have discussed that...
619 Views
Frontage Holdings IPO: Bull/Bear Case DCF Scenarios
Frontage Holdings (1521 HK) is a global contract research organisation (CRO) which is backed by Hangzhou Tigermed Consulting (300347 CH)....
638 Views
Frontage Holdings IPO: Risk-Reward Is Favourable at the Low-End of Price Range
Frontage Holdings (1521 HK) has launched its Hong Kong IPO at a price range of HK$2.55-3.20 per share to raise HK$1.27-1.60 billion ($160-200...
781 Views
Frontage Holdings (方达控股) IPO: Reasonable Valuation & Quality Cornerstones
Frontage Holdings, a pre-clinical CRO arm of A-share listed Hangzhou Tigermed Consulting (300347 CH), started book building today to raise up to...
805 Views
Viva Biotech (维亚生物) Post-IPO: SELL the Overvalued Incubator
Viva Biotech's IPO was priced at the top end with a very substantial oversubscription. We have highlighted in our earlier note that Viva Biotech's...
668 Views